Novo Nordisk to Invest €2.3 Billion in New High-Potency Manufacturing Site in Anagni, Italy

PharmTimesReport：

Global GLP-1 Track Raises Big Waves Again。Novo Nordisk recently announced officially，Will Invest €2.3 Billion Between 2025 and 2029，In Anagni, Lazio, central Italy（Anagni）Build a New High-Potency Formulation Production Base，Specifically used for the production of weight-loss and diabetes drugs。The project has been awarded by the Italian government.“National Interest Strategic Position”（Strategic National Interest, SNI），Expected to begin production as early as 2026。At that time，The number of employees at the facility will increase from the current 700 to 1,500.，Add 800 High-Quality Jobs。

Government Endorsement，Approval“Zero Resistance”

The Italian Prime Minister's Office pointed out in a recently issued cabinet decree，The Project“To ensure national pharmaceutical strategic autonomy、Strengthening the resilience of the European supply chain plays an irreplaceable role.”。By this identity，All environments、Construction、Operating License Will Enter“Green Channel”，Approval time reduced by more than 60%。Francesco, President of the Lazio Region·Roca（Francesco Rocca）Appointed as the Special Commissioner for the Project，With cross-departmental coordination、Special Authority for Land Acquisition and Infrastructure Support。Roca said：“Administrative efficiency and institutional coordination are the lubricants for the giant ship to set sail.，We will ensure that every procedure is fast and orderly.。”

Infrastructure First，€2.9 Million for Traffic Upgrades

To support future heavy logistics，The Regional Council of Lazio approved a special allocation of 2.9 million euros on the same day.，For widening the freight channel from the A1 highway Anani exit to the factory area，And build a new 2.7-kilometer railway branch line in the park.。The project is expected to be completed in synchronization with the civil construction of Novo Nordisk.。

Production Capacity？Official sources did not disclose the specific annual production capacity.，But industry insiders estimate，If using Wegovy（Semaglutide Injection）Surging global demand as a reference，The new base, once fully operational, can meet approximately 30% of the current annual supply gap in the European market.。

Europe“Nearshore Outsourcing”Speed up

The past three years，Novo Nordisk in Kalundborg, Denmark、U.S. Clayton Continues to Expand Production，Still Hard to Meet the Demand。This location selection is in Italy，Is regarded as its“Nearshore Outsourcing”Key Strategic Moves。

Italian Pharmaceutical Industry Association（Farmindustria）The chairman commented：“It extends Europe's most dynamic GLP-1 industrial chain from Northern Europe to the Mediterranean.，Italy leaps to become the central hub for obesity and diabetes drugs in Europe。”

Public-Private Partnership Paradigm

Project Adoption“Enterprise Investment + Central Authorization + Local Matching”The Three-Level Linkage Model：Novo Nordisk Invests 2.3 Billion Euros in Plant Construction、Equipment and Digital Production Line；The central government provides SNI status and tax benefits.；Lazio Region Responsible for Peripheral Infrastructure and Labor Training。

Officials from Italy's Ministry of Economy and Finance said，This model will be written into《White Paper on the Competitiveness of China's Pharmaceutical Industry》，Future Replication in Tumor Drugs、High-end fields such as vaccines。

Schedule

Stock Price Reaction

Copenhagen Stock Exchange: Novo Nordisk B shares rose 2.4% in early trading，Market Value Breaks Through 550 Billion US Dollars。Analysts generally expect，New capacity will significantly alleviate global supply shortages starting from 2027，And support the company to break through 50 billion Danish kroner in revenue by 2028。

Anani's vineyard remains lush and verdant.，But a future-oriented pharmaceutical artery is quietly taking shape underground.。The Landscape of Weight Loss Drugs in Europe，Rewrite accordingly.

[Note] This article was first published on the Yao Times Snowball platform on July 11, 2025.